Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China
- 255 Downloads
Long-acting injectable (LAI) formulations of antiretrovirals (ARVs) as pre-exposure prophylaxis (PrEP) could be an attractive alternative for men who have sex with men (MSM) who are interested in ARV-based biomedical prevention but will not use a daily pill. This study investigated interest in LAI-PrEP in a cohort of MSM in China and characterized how MSM willing to use only injectable PrEP differed from MSM who would use PrEP regardless of modality or not at all. Demographic, behavioral, and risk perception measures were collected and associations investigated. A licensed LAI-PrEP agent would increase the proportion interested in PrEP by 24.5% over oral PrEP alone. Combining interest in oral and injectable PrEP, 78.5% of the sample could be covered if reported interest in PrEP translated into actual uptake. Partnership factors differentiated those who would be willing to use only LAI-PrEP versus any PrEP modality, while higher self-perception of risk was associated with interest in LAI-PrEP versus no PrEP. The addition of a second PrEP modality could yield increased population coverage of PrEP. Social and behavioral research should be undertaken in parallel with clinical development of injectable PrEP agents to identify characteristics of those who are not interested in oral PrEP but would take advantage of ARV-based prevention with the introduction of an injectable product.
KeywordsHIV Biomedical HIV prevention PrEP China Men who have sex with men Long-acting injectable PrEP
Contributions from Dr. Meyers, Ms. Wu, Mr. Qian, were supported by the China AIDS Initiative under the leadership of Dr. David Ho. Dr. Meyers was also supported by Grant # UL1TR001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program. Dr. Sandfort’s contribution was supported by NIMH center Grant P30-MH43520 (P.I.: Robert Remien, PhD) to HIV Center for Clinical and Behavioral Research. The contribution of Drs. Shang, Xu, and Zhang were supported by the Mega-Projects of National Science Research for the 12th Five-Year Plan (2012ZX10001-006); they thank Dr. Yongjun Jiang for support. Dr. Glidden’s contributions were supported by Grant #s R03 AI120819 and R03 AI122908.
Compliance with Ethical Standards
Conflict of interest
The authors declares that they have no conflict of interest.
- 4.McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV 2015.Google Scholar
- 9.Peng B, Yang X, Zhang Y, Dai J, Liang H, Zou Y, et al. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. HIV AIDS. 2012;4:149–58.Google Scholar
- 11.Mijiti P, Yahepu D, Zhong X, Sun Y, Zhao T, Zhao Z, et al. Awareness of and willingness to use oral pre-exposure prophylaxis for HIV prevention among HIV-serodiscordant heterosexual couples: a cross-sectional survey in Xinjiang, China. PLoS ONE. 2013;8(7):e67392.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Xue H, Liu H, Cai L. Analysis of willingness and influencing factors for usage of pre-exposure prophylaxis among men who have sex with men. Chin J Prev Med. 2015;49(11):973–7.Google Scholar
- 17.Meyers K, Wu Y, Golub S. To switch or not to switch: anticipating choices in biomedical HIV prevention. Poster session presented at: HIV Research for Prevention Conference; October 17–21; Chicago. 2016.Google Scholar
- 19.Oldenburg CE, Le B, Huyen HT, Thien DD, Quan NH, Biello KB, et al. Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. Sex Health. 2016;13(5):465–73.Google Scholar
- 26.Mimiaga MJ, Closson EF, Battle S, Herbst JH, Denson D, Pitts N, et al. Reactions and receptivity to framing HIV prevention message concepts about pre-exposure prophylaxis for Black and Latino men who have sex with men in three urban US cities. AIDS Patient Care STDS. 2016;30(10):484–9.CrossRefPubMedGoogle Scholar
- 27.Underhill K, Morrow KM, Colleran C, Calabrese SK, Operario D, Salovey P, et al. Explaining the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention: a qualitative study of message framing and messaging preferences among US men who have sex with men. AIDS Behav. 2016;20(7):1514–26.CrossRefPubMedPubMedCentralGoogle Scholar